ethyl 4-methylthio-2-oxobutyrate | 84688-35-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 4-methylthio-2-oxobutyrate
• 英文别名: 4-methylsulfanyl-2-oxo-butyric acid ethyl ester；4-Methylmercapto-2-oxo-buttersaeure-aethylester；ethyl 4-methylsulfanyl-2-oxobutanoate
• CAS: 84688-35-7
• 化学式: C₇H₁₂O₃S
• 分子量: 176.236
• InChiKey: XAWVVCXKRKVDNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  68.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-methylthio-2-oxobutyrate 在 盐酸 作用下， 反应 9.0h， 以72%的产率得到4-甲硫基-2-氧代-丁酸
  参考文献：
  名称：

  Synthesis of deterium labeled plant ethylene precursor

  摘要：

  研究了制备 β-氘标记的 2-酮基-4-甲基丁酸的合成方法。首先用氯化铝作为冷凝剂使氯乙烯与草酰氯乙酯反应，然后加入甲硫醇。在吡啶中使用 NaBD4 还原法实现了氘标记。

  DOI：

  10.1002/jlcr.2580360505
• 作为产物：
  描述：

  2-(2-methylsulfanyl-ethyl)-acetoacetic acid ethyl ester 在 甲酸 、 nitrosylsulfuric acid 、 sodium ethanolate 作用下， 生成 ethyl 4-methylthio-2-oxobutyrate
  参考文献：
  名称：

  Chibata et al., Journal of the Agricultural Chemical Society of Japan, 1957, vol. 21, p. 333,335

  摘要：

  DOI：

文献信息

• [EN] PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER<br/>[FR] PROCÉDÉ DE PRODUCTION D'UN ESTER D'ACIDE CARBOXYLIQUE
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2012176930A1

  公开（公告）日：2012-12-27

  An object of the present invention is to provide a new process which can produce a carboxylic acid ester from an aldehyde. The object is achieved by a process for producing a carboxylic acid ester, including the step of mixing a compound represented by the formula (2-1): (wherein R2 represents an alkyl group optionally having a substituent, or the like; R3 and R4 each represent independently an alkyl group optionally having a substituent, or the like, or R3 and R4 are taken together to form a divalent hydrocarbon group optionally having a substituent, or the like; Y represents a group represented by -S- or a group represented by -N(R5)-; R5 represents an alkyl group optionally having a substituent, or the like, or R5 is taken together with R4 to form a divalent hydrocarbon group optionally having a substituent; and X- represents an anion), a base, an alcohol, oxygen and an aldehyde to oxidize the aldehyde.

  本发明的一个目的是提供一种新的过程，可以从醛中产生羧酸酯。该目的通过一种生产羧酸酯的过程实现，包括混合以下公式表示的化合物（2-1）的步骤：（其中R2代表一个烷基基团，可选地具有取代基，或类似物；R3和R4分别独立地代表一个烷基基团，可选地具有取代基，或类似物，或者R3和R4结合在一起形成一个二价碳氢基团，可选地具有取代基，或类似物；Y代表一个由-S-表示的基团或由-N(R5)-表示的基团；R5代表一个烷基基团，可选地具有取代基，或类似物，或R5与R4结合在一起形成一个二价碳氢基团，可选地具有取代基；X-代表一个阴离子），一种碱，一种醇，氧气和一种醛来氧化该醛。
• [EN] PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER<br/>[FR] PROCÉDÉ DE PRODUCTION D'ESTER D'ACIDE CARBOXYLIQUE
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2012026617A1

  公开（公告）日：2012-03-01

  The present invention relates to a process for producing a carboxylic acid ester, comprising a step of oxidizing an aldehyde by mixing an alcohol, carbon dioxide, the aldehyde and at least one compound selected from the group consisting of compounds represented by the formulae (2-1) and (2-2): wherein R2 represents an alkyl group optionally having a substituent or the like; R3 and R4 each independently represents an alkyl group optionally having a substituent or the like or R3 and R4 are linked together to form a divalent hydrocarbon group optionally having a substituent or the like; Y represents a group of -S- or a group of -N(R5)-, wherein R5 represents an alkyl group optionally having a substituent or the like, or R5 is linked to R4 to form a divalent hydrocarbon group optionally having a substituent; and R8 represents an alkyl group.

  本发明涉及一种生产羧酸酯的方法，包括通过混合醇、二氧化碳、醛和来自由式（2-1）和（2-2）所代表的化合物组成的群体中至少选取一种化合物，氧化醛的步骤：其中R2代表可能具有取代基等的烷基基团；R3和R4各自独立地代表可能具有取代基等的烷基基团，或者R3和R4连接在一起形成可能具有取代基等的二价碳氢基团；Y代表一个-S-基团或一个-N(R5)-基团，其中R5代表可能具有取代基等的烷基基团，或者R5连接到R4形成可能具有取代基的二价碳氢基团；R8代表一个烷基基团。
• Novel Inhibitors of Glutaminyl Cyclase
  申请人：Thormann Michael

  公开号：US20090269301A1

  公开（公告）日：2009-10-29

  The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, R 1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl; R 2 represents hydrogen; halogen; alkenyl; alkynyl; -alkenylaryl; -alkenylheteroaryl; alkyl, which may optionally be substituted by one or more groups selected from halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; -alkylcarbocyclyl; -alkylheterocyclyl; aryl; heteroaryl; heterocyclyl; -alkylaryl; -alkyl(aryl) 2 , -alkylheteroaryl; -aryl-heteroaryl; -heterocyclyl-aryl; -aryl-aryl; -heteroaryl-aryl; -heteroaryl-heteroaryl, and —C(O)R 4 ; R 3 represents halogen; alkyl optionally substituted by one or more groups selected from halogen, hydroxyl, alkoxy, thioalkyl, —C(O)OH and —C(O)O-alkyl; aryl; heteroaryl; —C(O)R 5 ; R 4 and R 5 independently represent alkyl, aryl, heteroaryl, -alkylaryl, -alkylheteroaryl, carbocyclyl, heterocyclyl, -alkylcarbocyclyl and -alkylheterocyclyl, with the proviso that, when R 1 is imidazolyl, -carbocyclyl-imidazolyl, -alkenyl-imidazolyl or -alkyl-imidazolyl, then R 3 may not be —C(O)R 5 .

  本发明涉及式（I）化合物，其组合物和用于疾病治疗的用途。其中，R1代表杂环芳基，-碳环芳基-杂环芳基，-烯基杂环芳基或-烷基杂环芳基；R2代表氢，卤素，烯基，炔基，-烯基芳基，-烯基杂环芳基，烷基，可以选择被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的烷基，可以选择被一个或多个从烷基，卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的碳环芳基，可以选择被一个或多个从烷基，卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的-烷基碳环芳基，-烷基杂环芳基，芳基，杂环芳基，杂环芳基，-烷基芳基2，-烷基杂环芳基，-芳基杂环芳基，-杂环芳基-芳基，-芳基-芳基，-杂环芳基-芳基，-杂环芳基-杂环芳基和-C（O）R4；R3代表卤素，烷基，可以选择被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的烷基，芳基，杂环芳基和-C（O）R5；R4和R5独立地代表烷基，芳基，杂环芳基，-烷基芳基，-烷基杂环芳基，碳环芳基，杂环芳基，-烷基碳环芳基和-烷基杂环芳基，但当R1是咪唑基，-碳环芳基-咪唑基，-烯基咪唑基或-烷基咪唑基时，R3不能是-C（O）R5。
• Inhibitors of glutaminyl cyclase
  申请人：Probiodrug AG

  公开号：US08278345B2

  公开（公告）日：2012-10-02

  The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, R1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl; R2 represents hydrogen; halogen; alkenyl; alkynyl; -alkenylaryl; -alkenylheteroaryl; alkyl, which may optionally be substituted by one or more groups selected from halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; -alkylcarbocyclyl; -alkylheterocyclyl; aryl; heteroaryl; heterocyclyl; -alkylaryl; -alkyl(aryl)2, -alkylheteroaryl; -aryl-heteroaryl; -heterocyclyl-aryl; -aryl-aryl; -heteroaryl-aryl; -heteroaryl-heteroaryl, and —C(O)R4; R3 represents halogen; alkyl optionally substituted by one or more groups selected from halogen, hydroxyl, alkoxy, thioalkyl, —C(O)OH and —C(O)O-alkyl; aryl; heteroaryl; —C(O)R5; R4 and R5 independently represent alkyl, aryl, heteroaryl, -alkylaryl, -alkylheteroaryl, carbocyclyl, heterocyclyl, -alkylcarbocyclyl and -alkylheterocyclyl, with the proviso that, when R1 is imidazolyl, -carbocyclyl-imidazolyl, -alkenyl-imidazolyl or -alkyl-imidazolyl, then R3 may not be —C(O)R5.

  本发明涉及公式（I）化合物，其组合物和用于疾病治疗的用途，其中R1代表杂环芳基，-碳环芳基-杂环芳基，-烯基杂环芳基或-烷基杂环芳基；R2代表氢，卤素，烯基，炔基，-烯基芳基，-烯基杂环芳基，烷基，该烷基可以选择性地被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代；碳环芳基，该碳环芳基可以选择性地被一个或多个从烷基，卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代；-烷基碳环芳基；-烷基杂环芳基；芳基；杂环芳基；杂环芳基；-烷基芳基2，-烷基杂环芳基；-芳基-杂环芳基；-杂环芳基-芳基；-芳基-芳基；-杂环芳基-芳基；-杂环芳基-杂环芳基，和-C（O）R4；R3代表卤素；烷基，该烷基可以选择性地被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代；芳基；杂环芳基；-C（O）R5；R4和R5独立地表示烷基，芳基，杂环芳基，-烷基芳基，-烷基杂环芳基，碳环芳基，杂环芳基，-烷基碳环芳基和-烷基杂环芳基，但是当R1为咪唑基，-碳环芳基-咪唑基，-烯基咪唑基或-烷基咪唑基时，R3不能为-C（O）R5。
• WO2008/55945
  申请人：——

  公开号：——

  公开（公告）日：——